A Phase I/II Study of JR-141 (Idursulfase) in Patients With Mucopolysaccharidosis Type II

Trial Profile

A Phase I/II Study of JR-141 (Idursulfase) in Patients With Mucopolysaccharidosis Type II

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Jun 2018

At a glance

  • Drugs Idursulfase (Primary)
  • Indications Mucopolysaccharidosis II
  • Focus Adverse reactions
  • Sponsors JCR Pharmaceuticals
  • Most Recent Events

    • 01 Jun 2018 Based on the results of this trial, JR-141 was designated under the SAKIGAKE Designation System in Japan in March 2018.
    • 13 Dec 2017 According to a JCR Pharmaceuticals Media Release, results of this study along with its preclinical study results will be announced at the 14th Annual WORLDSymposiumTM 2018.
    • 13 Dec 2017 Topline results published in the JCR Pharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top